Literature DB >> 33484663

Predisposition to cancer in children and adolescents.

Christian P Kratz1, Marjolijn C Jongmans2, Hélène Cavé3, Katharina Wimmer4, Sam Behjati5, Lea Guerrini-Rousseau6, Till Milde7, Kristian W Pajtler7, Lisa Golmard8, Marion Gauthier-Villars8, Rosalyn Jewell9, Catriona Duncan10, Eamonn R Maher11, Laurence Brugieres6, Kathy Pritchard-Jones12, Franck Bourdeaut13.   

Abstract

Childhood malignancies are rarely related to known environmental exposures, and it has become increasingly evident that inherited genetic factors play a substantial causal role. Large-scale sequencing studies have shown that approximately 10% of children with cancer have an underlying cancer predisposition syndrome. The number of recognised cancer predisposition syndromes and cancer predisposition genes are constantly growing. Imaging and laboratory technologies are improving, and knowledge of the range of tumours and risk of malignancy associated with cancer predisposition syndromes is increasing over time. Consequently, surveillance measures need to be constantly adjusted to address these new findings. Management recommendations for individuals with pathogenic germline variants in cancer predisposition genes need to be established through international collaborative studies, addressing issues such as genetic counselling, cancer prevention, cancer surveillance, cancer therapy, psychological support, and social-ethical issues. This Review represents the work by a group of experts from the European Society for Paediatric Oncology (SIOPE) and aims to summarise the current knowledge and define future research needs in this evolving field.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 33484663     DOI: 10.1016/S2352-4642(20)30275-3

Source DB:  PubMed          Journal:  Lancet Child Adolesc Health        ISSN: 2352-4642


  6 in total

Review 1.  Role of CBL Mutations in Cancer and Non-Malignant Phenotype.

Authors:  Davide Leardini; Daria Messelodi; Edoardo Muratore; Francesco Baccelli; Salvatore N Bertuccio; Laura Anselmi; Andrea Pession; Riccardo Masetti
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

Review 2.  The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.

Authors:  David R Ghasemi; Gudrun Fleischhack; Till Milde; Kristian W Pajtler
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

Review 3.  Diagnostic Strategies and Algorithms for Investigating Cancer Predisposition Syndromes in Children Presenting with Malignancy.

Authors:  Linda Rossini; Caterina Durante; Silvia Bresolin; Enrico Opocher; Antonio Marzollo; Alessandra Biffi
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

Review 4.  Multidisciplinary Treatment Strategies for Wilms Tumor: Recent Advances, Technical Innovations and Future Directions.

Authors:  Till-Martin Theilen; Yannick Braun; Konrad Bochennek; Udo Rolle; Henning C Fiegel; Florian Friedmacher
Journal:  Front Pediatr       Date:  2022-07-14       Impact factor: 3.569

5.  Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.

Authors:  Nathalie Rippinger; Christine Fischer; Hans-Peter Sinn; Nicola Dikow; Christian Sutter; Kerstin Rhiem; Sabine Grill; Friedrich W Cremer; Huu P Nguyen; Nina Ditsch; Karin Kast; Simone Hettmer; Christian P Kratz; Sarah Schott
Journal:  Cancer Med       Date:  2021-09-26       Impact factor: 4.452

6.  Clinical value of a screening tool for tumor predisposition syndromes in childhood cancer patients (TuPS): a prospective, observational, multi-center study.

Authors:  Raoul C Hennekam; Johannes H M Merks; Floor A M Postema; Saskia M J Hopman; Corianne A J M de Borgie; Cora M Aalfs; Jakob K Anninga; Lieke P V Berger; Fonnet E Bleeker; Charlotte J Dommering; Natasha K A van Eijkelenburg; Peter Hammond; Marry M van den Heuvel-Eibrink; Janna A Hol; Wijnanda A Kors; Tom G W Letteboer; Jan L C M Loeffen; Lisethe Meijer; Maran J W Olderode-Berends; Anja Wagner
Journal:  Fam Cancer       Date:  2021-03-09       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.